Stay in the loop! Subscribe to our newsletter and gain access to exclusive insights, trends, and news from the world of business and leadership. Don’t miss out!
Pfizer has stated that its respiratory syncytial virus (RSV) vaccine, Abrysvo, has exhibited a significant immune response in a late-stage
Pfizer has declared that its respiratory syncytial virus (RSV) vaccine, Abrysvo, has demonstrated a robust immune response in a late-stage clinical study involving adults aged 18 and older with compromised immune systems.
In the study, a single 120-microgram dose of Abrysvo was administered to 203 adults divided into four groups: individuals with lung cancer, end-stage kidney disease, autoimmune inflammatory disorders, and solid organ transplant recipients.
Due to their compromised immunity, these groups are particularly vulnerable to severe RSV-associated illnesses. The vaccine generated strong neutralizing antibodies against both RSV subtypes, RSV-A and RSV-B, across all groups, indicating its efficacy in this high-risk population.
Pfizer reported that Abrysvo was well-tolerated among participants, with a safety profile compatible with previous studies.
This suggests the vaccine is safe for adults with compromised immune systems, providing a new potential tool for protecting this vulnerable group from RSV.
Following these promising results, Pfizer plans to submit the data to regulatory agencies for review. Currently, Abrysvo is approved for use in people aged 60 and older and in pregnant women during the middle of the third trimester to protect their babies from RSV.
RSV typically causes cold-like symptoms but can lead to severe respiratory illness, especially in toddlers and older adults. In the United States alone, RSV is responsible for approximately 177,000 hospitalizations and 14,000 deaths annually among older adults. Developing and approving effective vaccines like Abrysvo are crucial in reducing these numbers and protecting at-risk populations.
This study marks a significant step forward in expanding the use of Abrysvo to additional high-risk groups, potentially offering better protection against RSV for those with compromised immune systems.
Volvo Cars has reduced its margin and revenue expectations for the second time this year. This
Safe Superintelligence (SSI), co-founded by former OpenAI chief scientist Ilya Sutskever, has successfully raised $1 billion
According to two sources familiar with the matter, Tesla plans to introduce a six-seat variant of
Cryptocurrency investors and industry executives plan to raise at least $100,000 for Vice President Kamala Harris
Warren Buffett’s conglomerate, Berkshire Hathaway, has reduced its stake in Bank of America (BofA) by selling
